

DRIVING PATIENT-CENTRIC ACCESS STRATEGIES

A KPI-DRIVEN APPROACH FOR GAUGING SUCCESS OF PATIENT ACCESS PROGRAMS BY LIFE SCIENCES ORGANIZATIONS




Introduction

The pharmaceutical environment is changing constantly because of new innovations, which are making the task of getting these life-changing treatments to patients difficult. Market access, a complex and always changing process, is essential in ensuring that these new drugs find their way to the people in need. The central piece in this intricate trip is the deliberative implementation of patient access programs (PAPs).

The Pivotal Role of Patient Access Programs (PAPs)

In the pharmaceutical industry, PAPs serve as a significant part of market access in a broader context. These are strategic initiatives that link patients and essential medications, ensuring that individuals can access treatments they need. By addressing barriers such as affordability, availability, and awareness, PAPs contribute significantly to enhancing patient access to medications. Moreover, this will aid the patients in effectively navigating complex healthcare systems, while allowing pharmaceutical organizations to meet regulatory requirements and demonstrate value to stakeholders - these represent the integral components of market access strategies. Finally, by facilitating patient access and support, PAPs not only improve health outcomes for individuals but also contribute to the overall success and sustainability of pharmaceutical products in the market.

This white paper proposes a KPI-driven approach for evaluating and improving patient focus on access strategies within PAPs. It investigates the issues related to finance, lack of awareness inherent in the pharmaceutical sector, current industry trends influencing patient-centric tactics, and offers insights into viable techniques like introducing a simple enrollment process and personalized patient support. By identifying and implementing key performance indicators (KPIs), life sciences organizations can assess the impact of their programs on patient outcomes, access, and satisfaction. This paper outlines various KPIs tailored to measure the success of PAPs, providing a comprehensive framework for organizations to optimize their patient access strategies.



Phase 1

Market Research & Requirement Assessment

Phase 2

Program Design &

Development

Phase 3

Partnering & Collaboration

Stakeholders

- · Market analysts
- · Healthcare professionals
- Patient advocates
- · Government agencies
- Pharmaceutical companies

Activities

- · Conduct market research
- · Identify unmet requirements
- Analyze regulations and policy trends

Expected Outcomes

- · Uncover PAP opportunities
- Understand needs and challenges
- Inform program design and resource allocation

Stakeholders

 Program development team (Pharmacist, Physician, Patient advocates, Program administrators)

Legal and Regulatory Experts

Activities

- Develop program concept
- · Define eligibility criteria
- · Establish benefit structure
- Design enrollment and support processes

Expected Outcomes

- Create well-defined program framework
- Ensure legal and regulatory compliance
- Tailor programs to address identified needs

Stakeholders

Pharmaceutical companies

- Healthcare providers
- Patient advocacy groups
- Social service organizations
- Community organizations

Activities

- Secure funding and partnerships
- Establish program infrastructure
- Develop communication and coordination strategies

Expected Outcomes

- Secure resources and expertise
- Leverage diverse perspectives
- Build networks for implementation and sustainability

Stakeholders

· Program administrators

- Healthcare providers
- · Patient navigators
- Outreach teams

Activities

- Develop and implement marketing and outreach campaigns
- Streamline enrollment processes
- Provide education and support to potential participants

Expected Outcomes

- · Raise program awareness
- Reach target populations
- Facilitate smooth enrollment and onboarding

Program Launch & Enrollment

Phase 5

Program Operations &

Management

Phase 4

Stakeholders

- · Program administrators
- Data analysts
- · Healthcare providers
- Pharmacists
- Patients

Activities

- Process applications and manage eligibility
- Manage financial assistance
- Track patient adherence and outcomes
- Monitor program performance and resource utilization

Expected Outcomes

- Ensure efficient program execution
- Provide ongoing support to patients
- Gather data for program improvement

Stakeholders

Program administrators

- Data analysts
- Patient Advocacy groups
- Independent evaluators

Activities

- Collect and analyze data on program performance
- · Patient outcomes
- Cost-effectiveness
- · Assess program impact
- · Identify areas for improvement

Expected Outcomes

- · Gain objective insights
- Inform data-driven modifications
- Demonstrate value and secure ongoing support

Phase 6

Monitoring, Evaluation & Continuous Improvement

External Document © 2024 Infosys Limited

Industry Trends

Trends Relevant Phase(s) **Improvement & Focus Areas** Examples • Programs are designed to address · There has been an increase of specific patient needs and about 38-fold in virtual care like preferences telehealth, and other patient portals which allow access to view · Patient voices heard through the health records, test results, partnerships with advocacy groups and communicate with healthcare Increased Focus on All Phases Patient-friendly communication and providers from the comfort of one's Patient-centricity support throughout enrollment and own home program operations · 40% of people are already using personalized cancer care, 28% are Personalized support services and interventions based on patient using mobile apps for diabetes feedback management like sugar fit, and post-surgery care management · Using patient feedback to refine and improve the program • People using wearable devices · Easier enrollment and information which track their health data have access through mobile apps and increased by 3-fold, and 80% of online portals Phase 4& Leveraging Technology for this population is ready to allow Phase 5 Telehealth consultations, data-Accessibility & Engagement their data to get transmitted to driven insights for personalized healthcare providers, enabling support, and real-time medication remote monitoring of chronic adherence tracking conditions Diverse mix of experts (doctors, data · Amgen and Xencor collaboration on folks etc.) for well-rounded solutions cancer immunotherapy to leverage each company's strength Expanding Partnerships & · Partnering with advocacy groups to Phase 3 understand patient needs and push Collaboration • Mylan & Biocon launched an insulin for wider access drug at a price far below their competitor Sanofi · Reduction of prices on specialty drug · Aligning program benefits with • A growth of 3% has been found in improved patient outcomes and the ACOs which brings together cost-effectiveness for value-based healthcare providers, including Phase 2& Integration with Value-based reimbursement structures hospitals and physicians to Phase 6 Care Models collaboratively manage and · Demonstrating program value coordinate care for a defined patient through data-driven evidence of population improved health outcomes and cost savings Ensuring program compliance with • Regulatory bodies are pushing for evolving regulations concerning the adoption of standardized APIs data privacy, transparency, and to enable the seamless exchange ethical considerations **Evolving Regulatory** of health information Phase 2

Engaging with policymakers to

influence regulations that promote

fair access and address emerging

challenges

• The 21st Century Cures Act aims

secure access to EHI

at providing interoperability and

Environment

Key Challenges

Below are some challenges faced by patients in accessing medications crucial to improve their health, issues they might face in current PAPs, and some limitations that such programs face in providing apt access and care to patients.



- Even with insurance, patients frequently face hefty co-pays and deductibles, and specialty-tier medications can be prohibitively expensive
- Many people struggle to afford critical medications, resulting in treatment abandonment and poorer health outcomes
- Hidden costs like dispensing fees, administrative fees, and costs related to tests or monitoring add to overall cost
- Insurance related problems like lack of coverage, underinsured, uninsured, and delay in prior authorization
- Understanding complex insurance plans, including formularies, prior authorization requirements, and appeals processes, can be challenging for patients



• Many patients are unaware of the various PAPs or eligibility criteria and the various steps involved, resulting in an information gap



 Patients are frustrated by fragmented experiences due to complex application processes, disconnected communication, and lack of integrated assistance




- Standardized programs are not tailored to individual requirements or financial situations
- Programs often respond to concerns rather than proactively address them



- Incomplete or inaccurate data due to manual entries impacts the review process, either excluding those who require aid or assisting ineligible individuals
- Managing sensitive patient data poses privacy and security risks
- Delays in acquiring new information may reduce PAP responsiveness to changing patient demands, thereby affecting the accuracy of eligibility assessments
- Monitoring and evaluating the effectiveness of PAPs necessitates extensive data collection and analysis, less data collection may restrict the program's capacity to check its effectiveness

Strategies to Make PAPs More Patient-centric

Enhanced patient access leads to increased provider productivity, as well as better patient and provider experiences at almost every touchpoint in the care continuum. It also favors the health system through strategic growth and numerous operational efficiencies. Below are some strategies that can help PAPs improve patient access by making them more patient-centric.



KPIs to Measure the Success of PAPs

Below are some KPIs which can be used to assess the impact of PAPs and if the patient-centric strategies are successful in catering to the needs of patients. The below KPIs are divided into business KPIs and data KPIs.

Business KPIs

These KPIs are primarily focused on measuring the overall program's success and effectiveness in achieving its business goals, i.e., to provide better medication access to patients by reducing costs and thus improving patient satisfaction.

il. No	Metric	Formula	Data Used	Responsible Teams
1	Program Awareness	(Number of patients aware of the program) / (Total target patient population)	Patient surveys, program enrollment data, website analytics	Marketing, Patient Engagement
2	Program Utilization	Number of patients actively enrolled and utilizing the PAP per month	Patient surveys, program enrollment data, website analytics	Patient Access, Enrollment, Reimbursement
3	Average Reduction in Specialty Pharma Drug Prices	((Average price of specialty drugs before negotiation) - (Average price of specialty drugs after negotiation)) / (Total number of specialty drugs included in the negotiation)	Pharmacy dispensing data, pricing data	Procurement and Contracting, Pricing Strategy and Market Access
4	Prior Authorization Success Rate	(Number of PA forms approved at first attempt) / (Total number of PA forms submitted)	CRM	Patient Access, Payer Relations, Reimbursement
5	Co-pay Assistance/ Coupon Utilization Rates	(Number of co-pay services or active coupons used) / (Total number of services or coupons delivered)	CRM, claims data	Patient Support, Financial Assistance
6	Decrease in Percentage of Patients Abandoning Treatment Due to Cost	(Abandonment rate in previous period) - (Abandonment rate in current period)	Patient surveys, pharmacy dispensing data, claims data	Patient Support and Adherence
7	Increase in Utilization of Generic/Lower-cost Alternatives	((Number of generic/lower-cost prescriptions filled) / (Total prescriptions filled)) x 100	Pharmacy dispensing data	Formulary Management
8	Reduction in Percentage of Patients Encountering Hidden Costs	((Number of patients reporting hidden costs / Total patients surveyed)) – ((Number of patients reporting hidden costs) / (Total patients surveyed in previous period))	Patient surveys, pharmacy data on dispensing fees	Patient Support and Financial Assistance
9	Reduction in Average Co-pay and Deductible Amounts	(Average co-pay/deductible in previous period) - (Average co-pay/deductible in current period)	Claims data from pharmacies or insurance companies	Reimbursement and Financial Assistance
10	Increase in Percentage of Low-income Patients Able to Afford Medication	((Number of low-income patients affording medication) / (Total low-income patients)) – ((Number of low-income patients affording medication) / (Total low-income patients in previous period))	Patient surveys, pharmacy data	Patient Support and Financial Assistance
11	Medication Adherence Rate	(Number of patients adherent to treatment) / (Total number of enrolled patients)	Claims data, patient surveys, pharmacy dispensing data	Patient Support, Adherence, Medical Affairs
12	Net Promoter Score (NPS)	((Number of Promoter Scores) / (Total Number of Respondents)) – ((Number of Detractor Scores) / (Total Number of Respondents))	Patient surveys, program feedback forms, social media mentions	Patient Experience, Patient Advocacy, Customer Experience

Data KPIs

These KPIs are designed to evaluate the performance of data collection, processing, and management within the program. They provide useful information aimed at assessing data quality, security, and how useful the data is for planning and managing the operations.

Sl. No	Metric	Formula	Data Used	Responsible Teams
1	Average Patient Satisfaction Score	Based on feedback surveys	Patient surveys, program feedback forms, social media mentions	Patient Experience, Patient Advocacy, Customer Experience
2	Average Time to Enrollment	(Total number of enrolled patients) / (Time taken for enrollment, e.g., in weeks or months)	Program enrollment data	Patient Access and Enrollment
3	Average Time to First Medication Access	Time from enrollment to receiving the first dose of medication	Pharmacy dispensing data	Patient Access and Enrollment
4	Completion Rate of Online Application	((Applications completed) / (Total applications started)) x 100	Application completion data, patient surveys	Patient Access and Enrollment
5	Patient Education Rate	(Number of patients completing educational programs) / (Total number of enrolled patients)	Educational module completion data from internal applications	Medical Affairs
6	Query Resolution Rate	(Number of successfully resolved patient queries or concerns) / (Total number of patient inquiries)	CRM data	Customer Service and Patient Support
7	Program Optimization Rate	Various analytics-driven metrics	Real-time analytics platform, program data	Program Management, Data Analytics and Operations
8	Data Completeness Rate	((Number of complete data fields) / (Total number of required data fields)) x 100	PAP database records, data collection protocols, compliance checklists	Data Management and Data Analytics
9	Health Outcome Achievement Rate	((Number of patients achieving predefined health outcomes) / (Total number of program participants)) x 100	Patient health records, outcome assessments, program participation data	Medical Affairs, Clinical Outcome and Program Management
10	Data Accuracy Rate	((Number of accurate data entries) / (Total number of data entries)) x 100	Data quality assessments, error logs	Data Management
11	Data Security Compliance Score	((Number of compliance checks passed) / (Total number of compliance checks)) x 100	Security audit reports, compliance assessments	Information Security
12	Data Processing Time	Average time taken to process new data entries	Timestamps of data entry and integration processes	Data Management and IT Operations

Whereas some KPIs may appear to both groups (for example, medication adherence rate), it is the emphasis that determines the categorization. In business-related KPIs the final aim is the outcome, while for data/analytics related KPIs the output is the process leading to the result, or the data quality itself.

By effectively utilizing both sets of KPIs, PAPs can gain a comprehensive understanding of their program's performance and identify areas for improvement across both business operations and data management practices.



Challenges – Strategies - KPIs



Conclusion


In conclusion, PAPs are instrumental in ensuring that innovative treatments reach the patients who need it the most within the healthcare system. This paper has highlighted how these PAPs can enhance market access and improve patient outcomes. By employing patient-centric strategies and utilizing KPIs, healthcare stakeholders can effectively gauge the effectiveness of their PAPs and make informed decisions to optimize patient access initiatives.

Organizations can create customized strategies for enhancing effectiveness by understanding the challenges, industry trends, and PAP value chain. Patient-centric access strategies are driven by integration with technology, cooperation with stakeholders, and attention to real-time data analytics.

For pharmaceutical businesses and other stakeholders in the healthcare industry, adaptability will continue to be vital as the healthcare landscape experiences transformations. Through innovation, collaboration, and a patient-centric approach, they will be able to address the challenges on their way and increase the impact of their PAPs which can translate into better access to the required medications and improved patient health.

References

- 1. https://www.mckinsey.com/industries/healthcare/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality
- 2. https://www.healthyagingpoll.org/reports-more/report/mobile-health-app-use-among-older-adults
- 3. https://www.nhlbi.nih.gov/news/2023/study-reveals-wearable-device-trends-among-us-adults
- 4. https://investors.amgen.com/news-releases/news-release-details/amgen-and-xencor-announce-strategic-collaboration-cancer/
- https://www.biocon.com/biocon-biologics-and-mylan-announce-launch-of-semglee-insulin-glargine-injection-in-the-u-s-to-expandaccess-for-patients-living-with-diabetes/
- 6. https://www.cms.gov/newsroom/press-releases/participation-continues-grow-cms-accountable-care-organization-initiatives-2024
- 7. https://hbr.org/2022/03/standardized-apis-could-finally-make-it-easy-to-exchange-health-records
- 8. https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2021/09/the-21st-century-cures-act-final-rule/#:~:text=The%20Cures%20Act%20final%20rule%20focuses%20on%20supporting,sharing%20of%20information%20%28also%-20known%20as%20information%20blocking%29



About the Authors



Saarthak Gupta
Consultant, ICLS, Infosys Consulting

Saarthak is a consultant in Infosys Consulting's Life Sciences practice within the LS Data Transformation Team with more than 5 years of professional experience. He has experience in Life Sciences, Healthcare, Information Technology and Ed-Tech industries. He has worked in multiple engagements on Data Analytics, Data Migration and Transformation, Data Quality Management, Reference Data Management and Net Revenue Management.



Sourav Pati
Consultant, ICLS, Infosys Consulting

Sourav Pati has 4 years of experience in the field of Healthcare, Insurance & Life Sciences. He has supported engagements in digital transformations, data migration, database creation & management. An analytics enthusiast who has helped in requirement gathering, Bl/analytics roadmap designing, implementation & documentation.

For more information, contact askus@infosys.com

Infosys®

© 2024 Infosys Limited, Bengaluru, India. All Rights Reserved. Infosys believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Infosys acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Infosys Limited and/ or any named intellectual property rights holders under this document.



